Cargando…

Efficacy of Grignard Pure to Inactivate Airborne Phage MS2, a Common SARS-CoV-2 Surrogate

[Image: see text] Grignard Pure (GP) is a unique and proprietary blend of triethylene glycol (TEG) and inert ingredients designed for continuous antimicrobial treatment of air. TEG has been designated as a ″Safer Chemical” by the US EPA. GP has already received approval from the US EPA under its Sec...

Descripción completa

Detalles Bibliográficos
Autores principales: Desai, Grishma, Ramachandran, Gurumurthy, Goldman, Emanuel, Esposito, William, Galione, Antony, Lal, Altaf, Choueiri, Toni K., Fay, Andre, Jordan, William, Schaffner, Donald W., Caravanos, Jack, Grignard, Etienne, Mainelis, Gediminas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001433/
https://www.ncbi.nlm.nih.gov/pubmed/36853925
http://dx.doi.org/10.1021/acs.est.2c08632
_version_ 1784904135216201728
author Desai, Grishma
Ramachandran, Gurumurthy
Goldman, Emanuel
Esposito, William
Galione, Antony
Lal, Altaf
Choueiri, Toni K.
Fay, Andre
Jordan, William
Schaffner, Donald W.
Caravanos, Jack
Grignard, Etienne
Mainelis, Gediminas
author_facet Desai, Grishma
Ramachandran, Gurumurthy
Goldman, Emanuel
Esposito, William
Galione, Antony
Lal, Altaf
Choueiri, Toni K.
Fay, Andre
Jordan, William
Schaffner, Donald W.
Caravanos, Jack
Grignard, Etienne
Mainelis, Gediminas
author_sort Desai, Grishma
collection PubMed
description [Image: see text] Grignard Pure (GP) is a unique and proprietary blend of triethylene glycol (TEG) and inert ingredients designed for continuous antimicrobial treatment of air. TEG has been designated as a ″Safer Chemical” by the US EPA. GP has already received approval from the US EPA under its Section 18 Public Health Emergency Exemption program for use in seven states. This study characterizes the efficacy of GP for inactivating MS2 bacteriophage—a nonenveloped virus widely used as a surrogate for SARS-CoV-2. Experiments measured the decrease in airborne viable MS2 concentration in the presence of different concentrations of GP from 60 to 90 min, accounting for both natural die-off and settling of MS2. Experiments were conducted both by introducing GP aerosol into air containing MS2 and by introducing airborne MS2 into air containing GP aerosol. GP is consistently able to rapidly reduce viable MS2 bacteriophage concentration by 2–3 logs at GP concentrations of 0.04–0.5 mg/m(3) (corresponding to TEG concentrations of 0.025 to 0.287 mg/m(3)). Related GP efficacy experiments by the US EPA, as well as GP (TEG) safety and toxicology, are also discussed.
format Online
Article
Text
id pubmed-10001433
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-100014332023-03-10 Efficacy of Grignard Pure to Inactivate Airborne Phage MS2, a Common SARS-CoV-2 Surrogate Desai, Grishma Ramachandran, Gurumurthy Goldman, Emanuel Esposito, William Galione, Antony Lal, Altaf Choueiri, Toni K. Fay, Andre Jordan, William Schaffner, Donald W. Caravanos, Jack Grignard, Etienne Mainelis, Gediminas Environ Sci Technol [Image: see text] Grignard Pure (GP) is a unique and proprietary blend of triethylene glycol (TEG) and inert ingredients designed for continuous antimicrobial treatment of air. TEG has been designated as a ″Safer Chemical” by the US EPA. GP has already received approval from the US EPA under its Section 18 Public Health Emergency Exemption program for use in seven states. This study characterizes the efficacy of GP for inactivating MS2 bacteriophage—a nonenveloped virus widely used as a surrogate for SARS-CoV-2. Experiments measured the decrease in airborne viable MS2 concentration in the presence of different concentrations of GP from 60 to 90 min, accounting for both natural die-off and settling of MS2. Experiments were conducted both by introducing GP aerosol into air containing MS2 and by introducing airborne MS2 into air containing GP aerosol. GP is consistently able to rapidly reduce viable MS2 bacteriophage concentration by 2–3 logs at GP concentrations of 0.04–0.5 mg/m(3) (corresponding to TEG concentrations of 0.025 to 0.287 mg/m(3)). Related GP efficacy experiments by the US EPA, as well as GP (TEG) safety and toxicology, are also discussed. American Chemical Society 2023-02-28 /pmc/articles/PMC10001433/ /pubmed/36853925 http://dx.doi.org/10.1021/acs.est.2c08632 Text en © 2023 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Desai, Grishma
Ramachandran, Gurumurthy
Goldman, Emanuel
Esposito, William
Galione, Antony
Lal, Altaf
Choueiri, Toni K.
Fay, Andre
Jordan, William
Schaffner, Donald W.
Caravanos, Jack
Grignard, Etienne
Mainelis, Gediminas
Efficacy of Grignard Pure to Inactivate Airborne Phage MS2, a Common SARS-CoV-2 Surrogate
title Efficacy of Grignard Pure to Inactivate Airborne Phage MS2, a Common SARS-CoV-2 Surrogate
title_full Efficacy of Grignard Pure to Inactivate Airborne Phage MS2, a Common SARS-CoV-2 Surrogate
title_fullStr Efficacy of Grignard Pure to Inactivate Airborne Phage MS2, a Common SARS-CoV-2 Surrogate
title_full_unstemmed Efficacy of Grignard Pure to Inactivate Airborne Phage MS2, a Common SARS-CoV-2 Surrogate
title_short Efficacy of Grignard Pure to Inactivate Airborne Phage MS2, a Common SARS-CoV-2 Surrogate
title_sort efficacy of grignard pure to inactivate airborne phage ms2, a common sars-cov-2 surrogate
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001433/
https://www.ncbi.nlm.nih.gov/pubmed/36853925
http://dx.doi.org/10.1021/acs.est.2c08632
work_keys_str_mv AT desaigrishma efficacyofgrignardpuretoinactivateairbornephagems2acommonsarscov2surrogate
AT ramachandrangurumurthy efficacyofgrignardpuretoinactivateairbornephagems2acommonsarscov2surrogate
AT goldmanemanuel efficacyofgrignardpuretoinactivateairbornephagems2acommonsarscov2surrogate
AT espositowilliam efficacyofgrignardpuretoinactivateairbornephagems2acommonsarscov2surrogate
AT galioneantony efficacyofgrignardpuretoinactivateairbornephagems2acommonsarscov2surrogate
AT lalaltaf efficacyofgrignardpuretoinactivateairbornephagems2acommonsarscov2surrogate
AT choueiritonik efficacyofgrignardpuretoinactivateairbornephagems2acommonsarscov2surrogate
AT fayandre efficacyofgrignardpuretoinactivateairbornephagems2acommonsarscov2surrogate
AT jordanwilliam efficacyofgrignardpuretoinactivateairbornephagems2acommonsarscov2surrogate
AT schaffnerdonaldw efficacyofgrignardpuretoinactivateairbornephagems2acommonsarscov2surrogate
AT caravanosjack efficacyofgrignardpuretoinactivateairbornephagems2acommonsarscov2surrogate
AT grignardetienne efficacyofgrignardpuretoinactivateairbornephagems2acommonsarscov2surrogate
AT mainelisgediminas efficacyofgrignardpuretoinactivateairbornephagems2acommonsarscov2surrogate